BeOne Medicines (NASDAQ:ONC) SVP Chan Henry Lee Sells 2,666 Shares of Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 2,666 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $360.00, for a total transaction of $959,760.00. Following the completion of the transaction, the senior vice president directly owned 812 shares in the company, valued at $292,320. This trade represents a 76.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Chan Henry Lee also recently made the following trade(s):

• On Thursday, July 30th, Chan Henry Lee sold 1,044 shares of BeOne Medicines stock. The stock was sold at an average price of $323.69, for a total transaction of $337,932.36.
• On Wednesday, July 8th, Chan Henry Lee sold 664 shares of BeOne Medicines stock. The shares were sold at an average price of $302.46, for a total transaction of $200,833.44.
• On Tuesday, June 16th, Chan Henry Lee sold 590 shares of BeOne Medicines stock. The shares were sold at an average price of $265.98, for a total transaction of $156,928.20.
• On Thursday, June 11th, Chan Henry Lee sold 428 shares of BeOne Medicines stock. The stock was sold at an average price of $257.63, for a total transaction of $110,265.64.
• On Monday, June 8th, Chan Henry Lee sold 871 shares of BeOne Medicines stock. The shares were sold at an average price of $270.42, for a total value of $235,535.82.

BeOne Medicines Stock Down 0.8%

Shares of BeOne Medicines stock opened at $356.01 on Friday. The company has a quick ratio of 3.06, a current ratio of 3.40 and a debt-to-equity ratio of 0.17. BeOne Medicines Ltd. – Sponsored ADR has a 12 month low of $253.95 and a 12 month high of $385.22. The business has a fifty day simple moving average of $302.92 and a 200 day simple moving average of $309.24. The stock has a market cap of $39.06 billion, a PE ratio of 62.68 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.65. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%.The business had revenue of $1.71 billion during the quarter, compared to the consensus estimate of $1.66 billion. Research analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 7.3 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. JPMorgan Chase & Co. lifted their price target on shares of BeOne Medicines from $415.00 to $425.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Guggenheim upped their price target on shares of BeOne Medicines from $420.00 to $430.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 18th. Wells Fargo & Company initiated coverage on shares of BeOne Medicines in a research report on Monday, May 4th. They set an “overweight” rating and a $400.00 target price on the stock. Finally, Nomura upgraded BeOne Medicines to a “strong-buy” rating in a research report on Monday, July 27th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $402.14.

More BeOne Medicines News

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: BeOne Medicines reported quarterly earnings of $2.05 per share, well above the $1.40 consensus estimate, while revenue reached approximately $1.71 billion, exceeding expectations and representing roughly 30% growth. The results reinforce the company’s commercial momentum. BeOne Medicines Q2 2026 earnings call highlights
• Positive Sentiment: UBS maintained its Buy rating on BeOne Medicines, signaling continued confidence in the company’s growth outlook and oncology portfolio. UBS maintains Buy rating on BeOne Medicines
• Positive Sentiment: BeOne’s collaboration with Revolution Medicines to fund and develop the Phase 3 RAS(ON) program could expand BeOne’s targeted-cancer pipeline and create future commercialization opportunities. Revolution Medicines’ shares rose following the announcement, suggesting investors viewed the deal as strategically meaningful. Revolution Medicines rises after BeOne-funded Phase 3 RAS(ON) deal
• Negative Sentiment: CEO John Oyler sold 240,810 shares across transactions dated August 10–12 for approximately $86.5 million, substantially reducing his direct ownership. The sales may pressure sentiment, particularly with ONC trading near its 52-week high, although they were executed under a pre-arranged Rule 10b5-1 plan and therefore may not reflect a new negative view of the company. SEC filing on John Oyler’s BeOne Medicines stock sales

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets boosted its position in BeOne Medicines by 100.6% during the fourth quarter. BNP Paribas Financial Markets now owns 193,951 shares of the company’s stock valued at $58,924,000 after acquiring an additional 97,244 shares during the last quarter. Renaissance Technologies LLC bought a new stake in BeOne Medicines in the 1st quarter valued at about $19,438,000. SEB Asset Management AB acquired a new position in BeOne Medicines during the 1st quarter worth approximately $16,653,000. Capital International Sarl raised its stake in BeOne Medicines by 2.7% during the 4th quarter. Capital International Sarl now owns 152,515 shares of the company’s stock worth $46,336,000 after buying an additional 3,956 shares during the period. Finally, Rokos Capital Management LLP bought a new position in BeOne Medicines in the first quarter worth approximately $4,256,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.